Acute Myeloid Leukemia: Changing Treatment Paradigms and Novel Agents in Development

Author(s): Heiko Konig, Joshua F. Zeidner

Journal Name: Current Cancer Drug Targets

Volume 20 , Issue 7 , 2020


Become EABM
Become Reviewer
Call for Editor

[1]
Strebhardt, K.; Ullrich, A. Paul Ehrlich’s magic bullet concept: 100 years of progress. Nat. Rev. Cancer., 2008, 8(6), 473-480.
[2]
Nelson, W.G. Commentary on huggins and hodges: Studies on prostatic cancer. Cancer Res., 2016, 76(2), 186-187.
[3]
Mrózek, K.; Marcucci, G.; Nicolet, D.; Maharry, K.S.; Becker, H.; Whitman, S.P.; Metzeler, K.H.; Schwind, S.; Wu, Y.Z.; Kohlschmidt, J.; Pettenati, M.J. Prognostic significance of the European leukemia net standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemia. J. Clin. Oncol., 2012, 30(36), 4515-4523.
[4]
Papaemmanuil, E.; Gerstung, M.; Bullinger, L.; Gaidzik, V.I.; Paschka, P.; Roberts, N.D.; Potter, N.E.; Heuser, M.; Thol, F.; Bolli, N.; Gundem, G. Genomic classification and prognosis in acute myeloid leukemia. N. Engl. J. Med., 2016, 374(23), 2209-2221.
[5]
Berman, E.; Wiernik, P.; Vogler, R.; Velez-Garcia, E.; Bartolucci, A.; Whaley, F.S. Long-term follow-up of three randomized trials comparing idarubicin and daunorubicin as induction therapies for patients with untreated acute myeloid leukemia. Cancer, 1997, 80(11 Suppl), 2181-2185.
[6]
Lee, J.H.; Kim, H.; Joo, Y.D. Cooperative Study Group A for Hematology. Prospective randomized comparison of idarubicin and high-dose daunorubicin in induction chemotherapy for newly diagnosed acute myeloid leukemia. J. Clin. Oncol., 2017, 35(24), 2754-2763.
[7]
Sievers, E.L. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukaemia in first relapse. Expert Opin. Biol. Ther., 2001, 1(5), 893-901.
[8]
Petersdorf, S.H.; Kopecky, K.J.; Slovak, M.; Willman, C.; Nevill, T.; Brandwein, J.; Larson, R.A.; Erba, H.P.; Stiff, P.J.; Stuart, R.K.; Walter, R.B. A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. Blood, 2013, 121(24), 4854-4860.


free to download

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 20
ISSUE: 7
Year: 2020
Published on: 14 July, 2020
Page: [471 - 472]
Pages: 2
DOI: 10.2174/156800962008200714125648

Article Metrics

PDF: 39
HTML: 5
PRC: 1